Joshua Liang, Clover Biopharmaceuticals CEO

With world still in sore need of dos­es, Clover says its Covid-19 vac­cine is 67% ef­fec­tive in Phase III

With con­cerns about the Delta vari­ant ris­ing and much of the world still in des­per­ate need of vac­cine dos­es, a Chi­nese biotech an­nounced Wednes­day that a new shot has shown pos­i­tive re­sults in a large tri­al against Covid-19, in­clud­ing new vari­ants.

Clover Bio­phar­ma­ceu­ti­cals an­nounced Wednes­day that its vac­cine can­di­date showed 79% ef­fi­ca­cy against the Delta vari­ant in a Phase II/III tri­al dubbed Spec­tra, and 67% ef­fec­tive against Covid-19 over­all.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.